Market Overview

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

Share:

HOOKIPA Pharma Inc. ("HOOKIPA"), a company developing a new class of
immunotherapies targeting infectious diseases and cancers based on its
proprietary arenavirus platform, today announced that it has achieved
its first research milestone in its collaboration and license agreement
with Gilead Sciences, Inc. ("Gilead"). The agreement, which was entered
into in June 2018, grants Gilead exclusive rights to HOOKIPA's TheraT®
and VaxWave® investigational arenavirus-based immunization
technologies for the development of immunotherapies against hepatitis B
virus (HBV) and human immunodeficiency virus (HIV).

HOOKIPA has completed the first research milestone by designing and
delivering 14 research-grade vectors to Gilead, along with the
characterization of these vectors and delivery of a data package for the
HIV program. Pursuant to the terms of the agreement, HOOKIPA is entitled
to a sizeable milestone payment from Gilead.

Joern Aldag, HOOKIPA's Chief Executive Officer said: "We are pleased to
have achieved our first milestone within the collaborative HIV program
with Gilead. This great achievement reflects our joint commitment to
develop and deliver new treatment options for patients suffering from
these infectious diseases. It also reflects HOOKIPA´s dedication to
further validate our technology in infectious disease."

Under the terms of the agreement, Gilead provided an upfront payment of
$10 million and will fund all research and development activities.
HOOKIPA will be eligible to receive milestone payments based upon the
achievement of specified development, regulatory, and commercial
milestones up to a total of approximately $400 million. HOOKIPA will
also be eligible to receive tiered royalties on net sales.

-END-

About HOOKIPA

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company
developing a new class of immunotherapeutics, targeting infectious
diseases and cancers based on its proprietary arenavirus platform that
is designed to reprogram the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, VaxWave®*,
a replication-deficient viral vector, and TheraT®*, a
replication-attenuated viral vector, are designed to induce robust
antigen specific CD8+ T cells and pathogen-neutralizing antibodies.
Both, VaxWave® and TheraT®, are designed to allow
for repeat administration while maintaining an immune response. TheraT®
has the potential to induce CD8+ T cell response levels previously not
achieved by other published immuno-therapy approaches. HOOKIPA's
"off-the-shelf" viral vectors target dendritic cells in vivo to activate
the immune system.

HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based
prophylactic vaccine to protect against cytomegalovirus infection and
has started dosing patients in a

Phase 2 trial in cytomegalovirus-negative patients awaiting kidney
transplantation from cytomegalovirus-positive donors. To expand its
infectious disease portfolio, HOOKIPA has entered into a collaboration
and licensing agreement with Gilead Sciences, Inc. to jointly research
and develop functional cures for HIV and Hepatitis B infections. HOOKIPA
is building a proprietary immuno-oncology pipeline by targeting virally
mediated cancer antigens, self-antigens and next-generation antigens.

TheraT® and VaxWave® are not approved anywhere
globally and their safety and efficacy have not been established.

Find out more about HOOKIPA online at www.hookipapharma.com.

*Registered in Europe; Pending in the US.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters in
Foster City, California.

Issued for and on behalf of HOOKIPA Pharma Inc. by Instinctif Partners.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com